The Week Ahead in Life Sciences

Research evidence excerpt

The Week Ahead in Life Sciences

(a weekly publication detailing key catalysts in our coverage universe)

July 6, 2026

(dollars in millions)

Events Highlighted in the Coming Month

Company/Event Ticker Rating Mkt cap Timing Anticipated Event

Biogen BIIB Neutral $31,907 2Q26 Potential Phase 2 results of BIIB091 (peripheral BTKi in MS)

Nektar Therapeutics NKTR Neutral $2,400 2Q26 End-of-Phase 2 meeting with FDA for rezpeg in AA

Odyssey Therapeutics ODTX Outperform $807 2Q26 Development candidate nomination for OD-004 (TSLPxIL-33)

TScan Therapeutics TCRX Outperform $69 2Q26 Initiate registrational trial for TSC-101 in heme malignancies

Beam Therapeutics BEAM Outperform $3,579 1H26 Complete HV dosing for BEAM-103 (CD117 mAb) component of ESCAPE

Pharvaris N.V. PHVS Outperform $2,359 1H26 Submit NDA for deucrictibant in on-demand treatment of HAE attacks

ORIC Pharmaceuticals ORIC Outperform $1,205 1H26 Start pivotal Ph 3 study of rinzimetostat (ORIC-944) in mCRPC

Vera Therapeutics VERA Neutral $2,957 July 7, 2026 PDUFA date for atacicept in IgAN

Beam Therapeutics BEAM Outperform $3,579 July 6-9, 2026 Preclinical data for BEAM-304 in PKU at FASEB Genome Engineering

Kalaris Therapeutics KLRS Outperform $113 July 17, 2026 Presentation of Phase 1a data of TH103 at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting

MannKind Corporation MNKD Outperform $1,396 July 26, 2026 PDUFA date for the sNDA for Furoscix auto-injector for edema associated with CHD and CKD

Nektar Therapeutics NKTR Neutral $2,400 July 2026 Begin Ph 3 study of rezpeg in AD

Corbus Pharmaceuticals CRBP Outperform $171 Summer 2026 Data from CANYON-1 investigating CRB-913 in obese patients

Source: Wedbush Securities, Inc.

Wedbush Healthcare Coverage (Part 1 of 9)